FINWIRES · TerminalLIVE
FINWIRES

$TEM

11 stories mentioning TEMUpdated 17d ago

Every FINWIRES story that references TEM, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.Tempus AI (TEM) shares were up more than 6% after the company said it has received approval from the US Food and Drug Administration for a tumor-only indication for its xT CDx next-generation sequencing platform used for comprehensive genomic profiling of solid tumors.Agios Pharmaceuticals (AGIO) stock was down more than 3% after the company said it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a phase 2b study failed to meet the company's threshold for further advancement.Natera (NTRA) shares were up more than 1% after the company said Diakonos Oncology will use its Signatera test to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II investigational immunotherapy trial.

$AGIO$IBB$NTRA$TEM$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.1% higher.Tempus AI (TEM) shares were up more than 7% after the company said it has received approval from the US Food and Drug Administration for a tumor-only indication for its xT CDx next-generation sequencing platform used for comprehensive genomic profiling of solid tumors.

$TEM
Wire

Tempus AI Expands Smart Physician Platform With Generative AI Tools

Tempus AI (TEM) has upgraded its Tempus Hub platform with agentic AI to streamline clinical workflows and enhance decision-making in oncology and precision medicine, the company said Wednesday.The enhanced system embeds a generative AI clinical co-pilot directly into Hub, enabling an agent-first experience that combines large language model capabilities with real-time diagnostic and genomic patient data, the company said.Tempus said the new architecture builds on its existing data infrastructure, including its Edge, Locker and Air systems, which support real-time data connectivity, secure storage and AI deployment at the point of care.The company shares were down over 1% in Wednesday trading.Price: $45.73, Change: $-0.93, Percent Change: -1.99%

$TEM
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Employment Data

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6% and the actively traded Invesco QQQ Trust (QQQ) was 0.8% higher in Friday's premarket activity amid April's employment data release.US stock futures were also higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.7% before the start of regular trading.The April employment report showed nonfarm payrolls rose by 115,000, above the 65,000 jobs increase expected in a survey compiled by Bloomberg, while March payrolls were revised up to a 185,000 increase and February payrolls were revised down to a 156,000 decrease.The University of Michigan's preliminary consumer sentiment reading for May and the wholesale inventory data for March will be released at 10 am ET.In premarket activity, bitcoin was up by 0.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.1% higher, Ether ETF (EETH) retreated by 0.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) fell 3%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained 1%, and the iShares US Technology ETF (IYW) was 0.7% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) advanced by 2.7%, while the iShares Semiconductor ETF (SOXX) rose by 2%.United Microelectronics (UMC) shares were down more than 3% in premarket activity after the company reported April sales of 22.66 billion New Taiwan dollars ($721.8 million), up 11% from a year earlier.Winners and Losers:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.2% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.7%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.5%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Toyota Motor (TM) shares were down more than 1% pre-bell after the company reported lower fiscal 2026 earnings.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was up 0.3%, while the iShares US Healthcare ETF (IYH) rose 2%. The iShares Biotechnology ETF (IBB) gained 0.5%.Tempus AI (TEM) stock was up more than 1% premarket after the company said it priced its upsized private placement of $400 million of 0% convertible senior notes due May 15, 2032.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.8%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.7% lower.Goldman Sachs BDC (GSBD) shares were down more than 1% pre-bell after the company reported lower Q1 adjusted net investment income and total investment income.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was flat and the iShares US Industrials ETF (IYJ) was 1.1% higher.Ferrovial (FER) stock was up more than 1% before the opening bell after the company reported higher Q1 adjusted earnings before interest, taxes, depreciation and amortization and revenue.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.02%.Scorpio Tankers (STNG) stock was down more than 1% before the opening bell after the company said it plans to offer $150 million of 1.75% convertible senior notes due 2031 via a private placement.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.1% to reach $94.92 per barrel on the New York Mercantile Exchange. Natural gas was up 0.2% at $2.77 per 1 million British Thermal Units. The United States Oil Fund (USO) fell by 1.3%, while the United States Natural Gas Fund (UNG) was 0.1% lower.Gold futures for May gained by 0.4% to reach $4,728.60 an ounce on the Comex. Silver futures advanced by 1.1% to $81.09 an ounce. SPDR Gold Shares (GLD) was 0.1% higher, and the iShares Silver Trust (SLV) rose by 1.8%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$FER$GLD$GSBD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPY$STNG$TEM$TM$UMC$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Research

Research Alert: CFRA Lowers Rating On Shares Of Tempus Ai To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $47 from $59, applying a 4.7x EV/sales multiple to our 2027 estimates, a discount to TEM's 7.7x average forward multiple since IPO in 2024. We narrow our 2026 loss per share view by $0.01 to -$0.44 and widen 2027's by $0.05 to -$0.14. While we expect TEM to report positive operating income and EPS by 2028, it is possible that operational disruption, competitive losses, or other developments delay the company's path toward profitability and drive further operating losses. With macroeconomic headwinds pressuring the health care sector, we favor some of TEM's competitors over the near-term, including peers in life sciences tools/services as well as the health care services sub-industry, despite the company's significant growth expectations. We also note risks around reimbursement, with TEM deciding to meter its MRD testing volumes to wait for more favorable pricing dynamics, as well as uncertainties around the timing of FDA approvals for various tests.

$TEM
Research

Research Alert: Tempus Ai Surpasses Q1 Expectations, Sales Guidance Raised

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Tempus AI reported Q1 2026 revenue of $348.1M (+36.1% Y/Y), beating the $345M consensus as both Diagnostics ($261.1M, +34.7%) and Data & Applications ($87.0M, +40.5%) segments delivered robust growth. Adjusted EPS of ($0.13) significantly outperformed the ($0.20) consensus and ($0.24) prior year result, while adjusted EBITDA improved $13.3M to ($2.8M) and adjusted gross margin reached 65.0% (up 360 bps Y/Y). Strong volume growth included 28% in Oncology testing, 54% in Hereditary following the Ambry Genetics acquisition in Q1 2025 (7% organic), and 500% in MRD testing to 6,500 tests performed. Following the strong beat, TEM raised 2026 revenue guidance to $1.59B-$1.60B (approximately 25% growth) while maintaining adjusted EBITDA guidance of $65M. We believe TEM's first Investor Day scheduled for May 29, 2026 should provide additional insights on market dynamics and long-term growth expectations, supporting the company's trajectory toward sustained profitability.

$TEM
Wire

Tempus AI Q1 Non-GAAP Loss Narrows, Revenue Rises; Revises 2026 Revenue Guidance

Tempus AI (TEM) reported a Q1 non-GAAP net loss late Tuesday of $0.13 per basic share, narrowing from a loss of $0.24 a year earlier.Analysts polled by FactSet expected a loss of $0.20.Revenue for the quarter ended March 31 was $348.1 million, up from $255.7 million a year earlier.Analysts surveyed by FactSet expected $345.4 million.The company raised its full-year 2026 revenue guidance to $1.59 billion to $1.60 billion from the prior forecast of $1.59 billion. Analysts expect $1.59 billion.Shares of Tempus AI were down more than 5% in after-hours activity.

$TEM
Wire

Tempus AI, USC Form Strategic Precision Medicine Partnership

Tempus AI (TEM) and the Keck School of Medicine of USC said Thursday they established a collaboration to advance artificial intelligence applications in healthcare delivery and clinical research.The arrangement targets operational upgrades for more than 1.5 million annual patient appointments throughout the university's Southern California medical network, the companies said.The health system will incorporate advanced molecular analysis into standard clinical procedures to facilitate personalized treatment plans, they said.This will allow automated screening systems to match eligible individuals with experimental therapies alongside software designed to identify patient management deficiencies, the companies added.Shares of the company were down over 5% in Thursday trading.Price: $52.37, Change: $-3.14, Percent Change: -5.66%

$TEM
Research

Research Alert: CFRA Maintains Hold Rating On Tempus Ai

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our 12-month target to $59 from $60, a 5.7x EV/sales multiple to our 2027 estimate, below TEM's 10x average forward multiple since IPO in 2024. We narrow our 2026 loss per share view by $0.01 to -$0.45 and widen 2027's by $0.04 to -$0.09. TEM recently announced an agreement with Merck & Co. (MRK 117 ****) to support oncology research and drug development via TEM's datasets and AI capabilities within the Lens platform. This follows a similar announcement in March, when TEM expanded its partnership with Gilead Sciences (GILD 139 ****), an existing large biotech customer. While management commentary regarding these announcements in yesterday's Needham Healthcare Conference was encouraging, we do not see these as transformative for near-term financial performance. We still expect near 25% sales growth in 2026, along with TEM's first full-year of positive EBITDA, as testing volume growth and higher reimbursement levels underpin the longer-term path toward profitability (positive EPS expected by 2028).

$TEM
Research

TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70

Tempus AI (TEM) has an average rating of overweight and mean price target of $72.40, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TEM
Research

Jefferies Initiates Tempus AI at Underperform With $35 Price Target

Tempus AI (TEM) has an average rating of overweight and mean price target of $72.40, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TEM

Track with the FINWIRES app suite

FolioX
FolioX
Track TEM in your portfolio
WheelAI
WheelAI
Analyze TEM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TEM